Ird Luxturna denied as non-formulary by Cigna?

Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Luxturna for IRD as Non-Formulary

Luxturna (voretigene neparvovec) is a one-time gene therapy priced at a level that places it well outside standard formulary tiers, and many Cigna plans either exclude it from the formulary entirely or manage it as a specialty carve-out requiring a separate authorization pathway. A non-formulary denial does not mean the therapy is clinically inappropriate — it means you need to pursue a formulary exception, which is the standard mechanism for obtaining coverage of a medically necessary drug not on the formulary.

For Luxturna specifically, the formulary exception argument is particularly strong: there is no formulary alternative that treats the same root cause (the absence of functional RPE65 protein in the retina). No other drug on any formulary addresses biallelic RPE65 mutation-associated retinal dystrophy.

## Your Federal Appeal Rights

• ERISA §503: Non-formulary denials are fully appealable under the full-and-fair review standard. You have the right to a clinical review by someone with expertise in retinal gene therapy.
• ACA §2719 external review: Available after internal appeal exhaustion, generally within four months of the denial notice. Because RPE65-associated retinal dystrophy causes progressive, irreversible vision loss, apply for expedited external review — this condition typically meets the urgent/serious health risk threshold.
• Formulary exception process: File a formulary exception request simultaneously with the internal appeal — it is often the faster track. Cigna's formulary exception criteria typically require demonstration that no formulary alternative is clinically appropriate.

## Concrete Appeal Steps

1. Obtain Cigna's formulary for your specific plan and confirm Luxturna's status (excluded vs. non-preferred tier). 2. Request Cigna's formulary exception criteria in writing. 3. Identify every drug Cigna considers a formulary alternative in the same therapeutic category — your retinal specialist will need to explain why each is not clinically equivalent. 4. Have your specialist draft a targeted formulary exception letter and a formal appeal letter. 5. Submit both simultaneously and track deadlines carefully. 6. If denied, file for expedited external review without delay.

## Documentation to Gather

• Genetic confirmation: Molecular test results confirming biallelic RPE65 pathogenic variants — establishes that your condition falls within Luxturna's unique FDA-approved indication.
• No-equivalent statement: A letter from your retinal specialist explicitly stating that no formulary alternative treats the same underlying genetic defect and that no substitute is clinically appropriate.
• Ophthalmology records: Retinal imaging, visual function tests (ERG, visual field, FST), and specialist consultation notes documenting disease stage and progression rate.
• FDA prescribing label: Demonstrates the specific, narrow indication for which Luxturna is approved and reinforces the argument that no equivalent exists.
• Urgency documentation: Specialist notes characterizing the rate of visual deterioration — relevant to both the formulary exception and an expedited external review request.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Supporting Evidence | |---|---| | No formulary alternative is clinically appropriate | Specialist letter; FDA label showing unique indication; genetic test confirming RPE65 mutation | | Drug is medically necessary | Ophthalmology records; progression documentation; prescriber letter | | [Any additional Cigna exception criteria] | [Exact documentation] |